As of September 30, 2020, the Québec Ministry of Health and Social Services has listed Lutathera on the Liste de Médicaments – Établissements. Lutathera will be reimbursed for GEP-NETs patients with advanced disease that is metastatic or not removable by surgery and has progressed despite standard somatostatin analogue therapy and whose ECOG (Eastern Clinical Oncology Group) score is 0 to 2. Please refer to the following link for the formulary listing:

Please see the press release:

ENGLISH –can be viewed at
FRENCH –can be viewed at